• Alessandro Casini, Pierre Fontana, Frédéric Glauser, Helia Robert-Ebadi, Marc Righini, and Marc Blondon.
• Service d'angiologie et d'hémostase, HUG et Faculté de médecine, 1205 Genève.
• Rev Med Suisse. 2020 May 6; 16 (692): 951-954.

AbstractSince the SARS-CoV-2 pandemic outbreak, growing evidence suggests that patients suffering from COVID-19 are at increased risk of thrombotic events. The sepsis-related activation of the coagulation combined with a high prevalence of common thrombotic risk factors could contribute to this prothrombotic state. Coagulation biomarkers could help in the identification of patients at risk of complications and mortality. The incidence of venous thromboembolic events appears to be increased, especially in severe COVID-19 patients. Based on that knowledge, several societies have provided recommendation on the prevention of venous thromboembolism. In this narrative review, we summarize available epidemiologic data on venous thromboembolism and recommendations on thromboprophylaxis in COVID-19.

15 keywords...

hide…